Kamat - Figure 10
AUA Guideline, 2016
FIG. 10: All guidelines for NMI bladder cancer recommend that for the highest-risk patients, definitive therapy must be considered. The 2016 AUA/SUO guidelines (Statement no. 28) say, "In a high-risk patient with persistent or recurrent disease within one year following treatment with two induction cycles of BCG or BCG maintenance, the clinician should offer radical cystectomy."[7]
References
Chang SS, Boorjian SA, Chou R, et al. Diagnosis and treatment of non-muscle invasive bladder cancer; unabridged version: American Urological Association (AUA)/Society of Urologic Oncology (SUO) guideline. Linthicum, MD:American Urological Association; 2016 https://www.auanet.org/documents/education/clinical-guidance/Non-Muscle-Invasive-Bladder-Cancer.pdf Accessed June 17, 2017.
